Across its top 9 institutional holders, INM's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 22/100, avg. turnover score 46/100).

Quarterly Activity

Recent Activity

+$205.8K

Total Buy Value

$26.2K

Total Sell Value

New buy4

Trim0

Add2

Sold out2

Net Buyers

Net Sellers

Smart Money Convergence

INM does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/INM

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-22

2026-07-22

No AI summary for this filing type

View Full Filing (SEC EDGAR)

2026-07-10

InMed Pharmaceuticals amended its merger agreement with Mentari Therapeutics. The amendment clarifies the sequence of steps in the merger, including a name change and a redomestication to Nevada, introduces a potential private placement by Mentari before closing, and clarifies the intended tax treatment. All other terms of the agreement remain unchanged.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

457637700

FAQ

Who are the top institutional investors holding INMED PHARMACEUTICALS INC (INM)?

Major stakeholders currently include Sabby Management, LLC ($142.0K), Citadel Advisors LLC ($30.3K), Virtu Financial LLC ($13.0K). Based on the latest 13F filings, there are a total of 9 tracked investment funds and institutions maintaining positions in INM.

What is the overall institutional sentiment toward INM recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $8.4K, driven by 6 managers accumulating shares while 2 reduced their exposure.

Which institutions have been selling or reducing their INM positions?

In the latest period, 0 funds trimmed their holdings, and 2 managers completely exited their positions. The aggregate reported sell value was $26.2K.

Are there any notable investors adding INM to their portfolios?

Yes, buying activity remains notable. 4 institutions opened new positions in {ticker}, and 2 existing holders added to their shares. The total reported buy value for the quarter amounted to $205.8K.

Related Stocks

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,151

Total reported value

$2.1T

3246 13F institutions increased their position this quarter

View detail

AMZN

Amazon.com INC

Institutions Holding

5,958

Total reported value

$1.5T

3029 13F institutions increased their position this quarter

View detail

NVDA

Nvidia CORP

Institutions Holding

5,766

Total reported value

$3.0T

2744 13F institutions increased their position this quarter

View detail

Developer Access

Access INM's institutional ownership data programmatically:

REST API

curl https://alphasmo.com/api/v1/market/stock/INM

CLI

npx alphasmo stocks get INM

Full API & MCP documentation →